The estimated Net Worth of Lauren Budden is at least $1.84 Million dollars as of 9 September 2024. Ms Budden owns over 1,506 units of Insulet stock worth over $1,505,068 and over the last 5 years she sold PODD stock worth over $333,443.
Ms has made over 1 trades of the Insulet stock since 2024, according to the Form 4 filled with the SEC. Most recently she sold 1,506 units of PODD stock worth $333,443 on 9 September 2024.
The largest trade she's ever made was selling 1,506 units of Insulet stock on 9 September 2024 worth over $333,443. On average, Ms trades about 84 units every 0 days since 2019. As of 9 September 2024 she still owns at least 6,609 units of Insulet stock.
You can see the complete history of Ms Budden stock trades at the bottom of the page.
Lauren Budden is the VP, Chief Accounting Officer & Controller at Insulet.
Lauren's mailing address filed with the SEC is C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON, MA, 01720.
Over the last 18 years, insiders at Insulet have traded over $64,849,299 worth of Insulet stock and bought 175,262 units worth $7,280,516 . The most active insiders traders include Jonathan Silverstein, Elizabeth H Weatherman, and Samuel D Colella. On average, Insulet executives and independent directors trade stock every 19 days with the average trade being worth of $2,473,148. The most recent stock trade was executed by Timothy J Scannell on 10 September 2024, trading 5,000 units of PODD stock currently worth $1,129,200.
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
Insulet executives and other stock owners filed with the SEC include: